Clinical Trials at University of Colorado Cancer Center
As of June 2026, 41 paid clinical trials are recruiting at University of Colorado Cancer Center, located at 13001 E 17TH PL, AURORA, CO 80045-2570, phone (303) 724-5000 in Aurora, Colorado. Active studies at this site cover conditions such as Breast Cancer, Obesity and Heart Failure. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
41 clinical trials at University of Colorado Cancer Center
·Clear filters·↓ Download CSVBfedBwell INSPIRE Pilot
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Microbiome in Head and Neck Squamous Cell Carcinoma
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
A Study of BG-C477 in Participants With Advanced Solid Tumors
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Relationships Between Physical Activity and Different Measures of Fatigue in Cancer Survivors
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
About research studies in Aurora
Aurora has approximately 1,099 recruiting research studies across a wide range of therapeutic areas. Colorado hosts the University of Colorado Anschutz Medical Campus, National Jewish Health, and Children's Hospital Colorado, with strong programs in pulmonology, oncology, and cardiovascular research.
Common conditions studied in Aurora
- Breast Cancer (27 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Obesity (18 active studies). Obesity trials evaluate GLP-1 and GIP receptor agonists, novel metabolic drugs, and combined lifestyle interventions for sustainable weight loss.
- Heart Failure (13 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Type 1 Diabetes (13 active studies). Type 1 diabetes research investigates immune-modulating therapies, stem cell–derived islet replacement, and closed-loop insulin delivery systems.
- Colorectal Cancer (12 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Melanoma (12 active studies). Melanoma trials test immune checkpoint inhibitors, adoptive cell therapies, and BRAF/MEK targeted combinations in both early and metastatic disease.
Leading research sponsors in Aurora
- University of Colorado, Denver
- National Cancer Institute (NCI)
- VA Office of Research and Development
- Children's Oncology Group
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Colorado are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Colorado trials are additionally subject to the Colorado Privacy Act (CPA), which adds consumer data-protection requirements to federal baseline standards.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Aurora. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Aurora
Hipa.ai aggregates every recruiting study in Aurora from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Aurora?
There are approximately 1,099 recruiting clinical trials in Aurora, Colorado listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Aurora pay participants?
Most recruiting trials in Aurora compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Aurora?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Aurora?
The most common conditions under active study in Aurora include Breast Cancer (27), Obesity (18), Heart Failure (13), Type 1 Diabetes (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Aurora?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Aurora on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Aurora?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Aurora?
Recruiting research sites in Aurora include Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, University of Colorado, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Aurora right now?
The largest active categories in Aurora are Cancer & tumors (315), Diabetes & metabolic (85), Neurology & pain (73). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Colorado Cancer Center?
University of Colorado Cancer Center is located at 13001 E 17TH PL, AURORA, CO 80045-2570. Use the Google Maps link in the intro above to get directions.
How do I contact University of Colorado Cancer Center?
You can reach University of Colorado Cancer Center by phone at (303) 724-5000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.